Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Sells $21,204.48 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) insider Ronald Silver sold 12,048 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $21,204.48. Following the transaction, the insider now owns 279,655 shares of the company’s stock, valued at approximately $492,192.80. This trade represents a 4.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock opened at $1.92 on Friday. The firm has a 50 day simple moving average of $3.57 and a 200-day simple moving average of $4.15. Ironwood Pharmaceuticals, Inc. has a 1-year low of $1.59 and a 1-year high of $15.65. The stock has a market cap of $307.25 million, a price-to-earnings ratio of -64.00 and a beta of 0.29.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds have recently made changes to their positions in IRWD. Pacer Advisors Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 26.6% in the 3rd quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company’s stock worth $46,473,000 after acquiring an additional 2,372,183 shares during the last quarter. Stonepine Capital Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 1,982.8% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $4,120,000 after acquiring an additional 951,988 shares during the last quarter. State Street Corp lifted its holdings in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after acquiring an additional 677,024 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 5.5% in the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock worth $40,163,000 after acquiring an additional 469,043 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter worth approximately $1,641,000.

Analyst Upgrades and Downgrades

IRWD has been the subject of several research reports. StockNews.com cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. JMP Securities dropped their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research note on Thursday, January 30th. Finally, Craig Hallum dropped their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.